记忆CD8^(+)T细胞相关免疫治疗在肝细胞癌中的研究进展  

Research progress in associated immunotherapy of memory CD8^(+) T cells in hepatocellular carcinoma

作　　者：张小余 徐细明[1] ZHANG Xiaoyu;XU Ximing(The Third Department of Tumor,Tumor Center of Renmin Hospital of Wuhan University,Hubei Province,Wuhan430000,China)

机构地区：[1]武汉大学人民医院肿瘤中心肿瘤三科,湖北武汉430000

出　　处：《中国医药导报》2022年第19期45-48,69,共5页China Medical Herald

基　　金：国家自然科学基金资助项目(31971166)。

摘　　要：肝细胞癌(HCC)是最常见的原发肝癌类型,给患者带来了沉重经济和健康负担。随着HCC免疫研究的进展,记忆CD8^(+)T细胞对HCC的免疫抑制作用也被更加清楚地认识。本文从记忆CD8^(+)T细胞各个亚群的特异分布、表面分子和功能出发,梳理了与之相关的外源性和内源性的免疫治疗。前者包含以记忆CD8^(+)T细胞为载体的过继免疫治疗,后者则主要包含以免疫抑制分子为靶点的靶向治疗。记忆CD8^(+)T细胞相关免疫治疗在动物和临床试验中均对HCC展现了良好的效果,有望给HCC治疗带来新的曙光。Hepatocellular carcinoma(HCC),as the most common type of primary liver cancer,leads to heavy economic and health burdens to patients.With the progress of immunology research about HCC,the role of memory CD8^(+)T cells in HCC suppression is gradually recognized.This article reviewes exogenous and endogenous immunotherapy based on the specific distribution,surface molecules,and functions of memory CD8^(+)T cells subsets.The exogenous immunotherapy mainly contains adoptive immunotherapy carried by memory CD8^(+)T cells,while the endogenous mainly contains targeted therapies targeting immunosuppressive molecules.Memory CD8^(+)T cell-associated immunotherapy has shown good efficacy in both animal and human trials in HCC,and it is hopeful for a bright future to the treatment of HCC.

关 键 词：记忆CD8^(+)T细胞 肝细胞癌 靶向治疗 过继免疫治疗 

分 类 号：R575[医药卫生—消化系统]